Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 69Gynecologic 21Gastrointestinal 10Genitourinary 9Classical hematology 5Thoracic 3Sarcoma 2Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 5Multiple Myeloma 3Wilms Tumor 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Breast Neoplasms 2Xanthogranuloma, Juvenile 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Sarcoma, Ewing 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 10pembrolizumab 9Therapeutics 8Flow Cytometry 6Radiotherapy 5Gemcitabine 5Blood Specimen Collection 5Surveys and Questionnaires 4Sirolimus 4Psychiatric Rehabilitation 4Peripheral Blood Stem Cell Transplantation 4Paclitaxel 4Nivolumab 4Methods 4Ipilimumab 4Filgrastim 4Exercise 4Drug Therapy 4Doxorubicin 4Capecitabine 4copanlisib 3aldesleukin 3Rituximab 3Polymerase Chain Reaction 3Immunologic Techniques 3Immunoglobulin G 3Immunoenzyme Techniques 3Fluorodeoxyglucose F18 3Early Intervention, Educational 3Disulfides 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × olaparib × Lymphoid × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03205176 2021-05-06

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

AstraZeneca

Phase 1 Completed
49 enrolled
BreastGastrointestinalGenitourinaryGynecologicLymphoid

Breast Neoplasms, Lymphoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡